Navigation Links
Orexigen Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
Date:11/27/2013

SAN DIEGO, Nov. 27, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the 25th Annual Piper Jaffray Healthcare Conference in New York. The presentation is scheduled for Tuesday, December 3rd  at 11:00 a.m. Eastern Time. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave, which the Company is evaluating in the Light Study, a cardiovascular outcomes trial being conducted under a Special Protocol Assessment (SPA) with the FDA. Based on successful results of the Light Study, the Company plans to resubmit the Contrave NDA to the FDA with potential approval by June 2014.The Company's other product candidate, Empatic, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com. Orexigen Contact:

Media Contact:  McDavid Stilwell

Denise PowellVP, Corporate Communications and Business Development

BrewLife(858) 875-8629

(510) 703-9491


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Orexigen Announces Successful Interim Analysis of Contrave Light Study
2. Orexigen Therapeutics to Host Contrave Light Study Interim Analysis Conference Call and Webcast
3. Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
4. Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
5. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
6. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
7. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
8. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
9. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
10. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
11. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 27, 2015 OpportunityAnalyzer: Sepsis ... Sepsis patients suffer from a series of diverse ... toxins in the blood or tissues, which cause a ... leading to mortality rates near 50% depending on disease ... national healthcare systems of the global marketplace, which for ...
(Date:5/27/2015)... YORK , May 27, 2015 PharmaPoint: ... Forecast and Market Analysis to 2022 - Event-Driven Update ... dominated by generics and GlaxoSmithKline,s Benlysta is the only ... more than 50 years. Following Benlysta,s launch, patients, uptake ... price-tag Benlysta has managed to grow the lupus market ...
(Date:5/27/2015)... May 27, 2015 ... the addition of the  "Asia Pacific Ultrasound ... (2014 - 2019)"  company profile to ... , , ,Ultrasound is a type of ... look at body parts and structures inside ...
Breaking Medicine Technology:OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 2OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 3OpportunityAnalyzer: Sepsis - Opportunity Analysis and Forecasts to 2021 4PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update 2PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update 3Asia Pacific Ultrasound Devices Market Report 2015 - Growth, Trends And Forecasts 2014 - 2019 2
... HistoRx, the leader in quantitative immunohistochemistry, has earned ... elements of digital microscopy standardization.  Combined with patents ... & Trademark Office advance the Company,s proprietary position ... dominant role in the industry.  ...
... Feb. 28, 2012  On February 28th, 2012, the New ... those interested in speaking at its 2012 Digital Health ... York City,s Pier Sixty. At NYeC,s ... New York City—over 600 healthcare providers, healthcare technology companies, ...
Cached Medicine Technology:HistoRx Achieves Dominant Intellectual Property Position in Standardization of Results from Digital Pathology Instruments 2HistoRx Achieves Dominant Intellectual Property Position in Standardization of Results from Digital Pathology Instruments 3Call for Speakers: New York's Digital Health Conference 2012 2
(Date:5/27/2015)... Continuing its commitment to finding a cure and ... SmartPractice® donated $25,000 to HonorHealth Breast Health ... President of Human Resources Meg Mosher and SmartScrubs Director ... Paulla Miller, Sherry Gage, Dr. Linda Greer and Ginger ... April 30. The center is located at 19646 North ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 Dr. Omar ... based in Stamford, CT has been selected as part ... first physicians nationwide (and the only physician in Connecticut) ... which allows for the removal of submental fat (double ... no recovery time, no surgery and minimal risks. Dr. ...
(Date:5/27/2015)... NJ (PRWEB) May 27, 2015 ... Network (BCAN) , whose mission is to advance research, ... cancer, have joined forces to battle the fifth most ... in the bladder’s lining start to grow out of ... and their families at every stage of the cancer ...
(Date:5/27/2015)... CompanionDx announced that its abstract “Role ... personalized cancer therapy: Non-small cell lung cancer (NSCLC) case ... Oncology (ASCO) as part of their annual meeting, May ... and clinical data used for the study was obtained ... reports improved patient outcomes from a preliminary analysis of ...
(Date:5/27/2015)... Phoenix, Arizona (PRWEB) May 27, 2015 ... use of their advanced programmatic marketing technology, they have ... provides advertising support on a regional level for seven ... Honda's marketing was through television and radio media. In ... and, with the help of Genius Monkey , ...
Breaking Medicine News(10 mins):Health News:SmartPractice Donates $25,000 to HonorHealth Breast Health and Research Center 2Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 2Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 3Health News:CURE® Magazine and Bladder Cancer Advocacy Network Align to Increase Awareness of Fifth Most Common Type of Cancer 2Health News:CURE® Magazine and Bladder Cancer Advocacy Network Align to Increase Awareness of Fifth Most Common Type of Cancer 3Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 2Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 3Health News:Genius Monkey Boosts Utah Honda Dealers Website Traffic 142% 2
... up to offer customized map solutions. , ... Seattle ... Mapscape B.V. have announced a working relationship that will allow mutual ... solution provided by both companies. , , ,In this relationship, Birdstep ...
... city kids moving, study finds , , FRIDAY, Nov. 14 (HealthDay ... city kids keep excess pounds at bay, according to a ... snapshots in time, and shown that for children in densely ... of obesity. Our new study of over 3,800 inner-city children ...
... treatment and outcomes are different among races , , FRIDAY, Nov. ... have a different genetic makeup in blacks than in whites, ... different among races, a new study says. , In ... of the epidermal growth factor receptor (EGFR) gene and fewer ...
... An intra cellular pathway not previously linked to breast ... is highly lethal and disproportionately over-represented in African American ... destroy proteins and represents a class of genes called ... cells degrade the tumor suppressor gene p27 by making ...
... in Lowering High Blood Pressure Naturally. , ... Phoenix, ... that specializes in all-natural life improvement products, announced the release of ... :Guided Breathing for Low Blood Pressure, this week., , , , ...
... patients more time, developers say , , FRIDAY, Nov. 14 ... developed a technology that can rapidly send an icy ... protect specific organs during certain health emergencies. , ... body through a small intravenous catheter directly into a ...
Cached Medicine News:Health News:Birdstep Technology Partners with Mapscape to Offer RDM Embedded Content Solution for Navigation Systems 2Health News:Birdstep Technology Partners with Mapscape to Offer RDM Embedded Content Solution for Navigation Systems 3Health News:Greener Neighborhoods Mean Slimmer Children 2Health News:Lung Cancer Genetics Different in Black Patients: Study 2Health News:UCLA scientists find cell pathway driving a deadly sub-type of breast cancer 2Health News:UCLA scientists find cell pathway driving a deadly sub-type of breast cancer 3Health News:High Blood-Pressure Patients Can See Improvement Through Guided Breathing 2Health News:IV 'Ice Slurry' Quickly Cools Body for Surgeries 2
... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
... Centuries of German ... finest surgical instrumentation in ... makes them available to ... the coveted Meisterbrief certificate, ...
Protects the eye from symptoms caused by "dry eye, medical conditions, drug reactions and environmental factors. Forms a moisture chamber over the eye area during rest....
... Medtronic Ophthalmics offers the most comprehensive ... Eraser Instruments for Cataract incision, Glaucoma ... discrete coagulation is achieved with minimal ... necrosis. Straight eraser styles are available ...
Medicine Products: